The iconic rise of copyright’s flagship product presented a considerable chance for investors , but its patent has ended, creating a challenging landscape. Alternative versions have appeared in the arena, eroding revenues and putting pressure on profit margins . While leading drug companies maintain a foothold in this field , the outlook remains